Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 2
1961 2
1962 9
1963 18
1964 43
1965 53
1966 42
1967 41
1968 48
1969 46
1970 54
1971 40
1972 53
1973 68
1974 75
1975 66
1976 55
1977 55
1978 63
1979 59
1980 81
1981 48
1982 79
1983 63
1984 63
1985 64
1986 54
1987 55
1988 48
1989 76
1990 78
1991 61
1992 52
1993 53
1994 62
1995 67
1996 48
1997 43
1998 46
1999 64
2000 75
2001 77
2002 82
2003 71
2004 62
2005 64
2006 74
2007 57
2008 45
2009 39
2010 34
2011 36
2012 39
2013 33
2014 21
2015 25
2016 27
2017 15
2018 22
2019 26
2020 25
2021 30
2022 35
2023 24
2024 26
2025 30
2026 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,112 results

Results by year

Filters applied: . Clear all
Page 1
Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain.
Blair HA. Blair HA. Drugs. 2024 Apr;84(4):449-457. doi: 10.1007/s40265-024-02018-3. Epub 2024 Apr 9. Drugs. 2024. PMID: 38592603 Free PMC article. Review.
The gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix decreases estradiol and progesterone levels, while the addition of estradiol/norethisterone acetate mitigates hypoestrogenic effects including bone mineral density (BMD) loss and vasomoto …
The gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix decreases estradiol and progesterone levels, while the additi …
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids.
Syed YY. Syed YY. Drugs. 2022 Oct;82(15):1549-1556. doi: 10.1007/s40265-022-01790-4. Epub 2022 Nov 4. Drugs. 2022. PMID: 36331779 Free PMC article. Review.
An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate (Ryeqo( ); Myfembree( )) has been approved for the management of heavy menstrual bleeding associated with uterine fibroids in the USA and management of …
An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate (Ryeqo( ); M …
Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study.
Donnez J, Petraglia F, Taylor H, Becker CM, Becker S, Herrera FC, Bestel E, Hori S, Dolmans MM. Donnez J, et al. Fertil Steril. 2025 Oct;124(4):737-748. doi: 10.1016/j.fertnstert.2025.06.016. Epub 2025 Jun 19. Fertil Steril. 2025. PMID: 40543832 Free article. Clinical Trial.
OBJECTIVE: To evaluate whether oral linzagolix administered once daily for up to 52 weeks (extension study) at a dose of 100 mg or 200 mg with or without hormonal add-back therapy (ABT) (1.0 mg estradiol; 0.5 mg norethisterone acetate) can maintain the efficacy and …
OBJECTIVE: To evaluate whether oral linzagolix administered once daily for up to 52 weeks (extension study) at a dose of 100 mg or 200 mg wi …
Once-a-month injectable contraceptives.
d'Arcangues C. d'Arcangues C. World Health Forum. 1993;14(4):439-40. World Health Forum. 1993. PMID: 8185807
Cyclofem contains 25 mg medroxyprogesterone acetate and 5 mg estradiol cypionate, while Mesigyna is comprised of 50 mg norethisterone enanthate and 5 mg estradiol valerate. ...
Cyclofem contains 25 mg medroxyprogesterone acetate and 5 mg estradiol cypionate, while Mesigyna is comprised of 50 mg norethister …
Efficacy and safety of ultra-low-dose estradiol and norethisterone in postmenopausal Brazilian women.
Bonassi Machado R, Pompei LM, Nahas EAP, Nahas-Neto J, Costa-Paiva LD, Del Debbio SYO, Badalotti M, Wender MCO, Cruz AM. Bonassi Machado R, et al. Climacteric. 2023 Aug;26(4):401-407. doi: 10.1080/13697137.2023.2190507. Epub 2023 Mar 28. Climacteric. 2023. PMID: 36977423 Free article.
OBJECTIVE: This study aimed to evaluate the efficacy and safety of oral ultra-low-dose continuous combination of 17beta-estradiol (17beta-E2) and norethisterone acetate (NETA) in postmenopausal Brazilian women. ...
OBJECTIVE: This study aimed to evaluate the efficacy and safety of oral ultra-low-dose continuous combination of 17beta-estradiol (17 …
Breast and endometrial safety of micronised progesterone versus norethisterone acetate in menopausal hormone therapy (PROBES): study protocol of a double-blind randomised controlled trial.
Lundell C, Stergiopoulos N, Blomberg L, Ujvari D, Schuppe-Koistinen I, Kopp-Kallner H, Iliadis SI, Skalkidou A, Hirschberg AL. Lundell C, et al. BMJ Open. 2024 Oct 23;14(10):e082749. doi: 10.1136/bmjopen-2023-082749. BMJ Open. 2024. PMID: 39448218 Free PMC article.
The objective of the Progesterone Breast Endometrial Safety Study is to investigate breast and endometrial safety of mP versus norethisterone acetate (NETA) in continuous combination with oral oestrogen. METHODS AND ANALYSIS: This multicentre trial, conducted at three Univ …
The objective of the Progesterone Breast Endometrial Safety Study is to investigate breast and endometrial safety of mP versus norethiste …
Got guts? Need nerve!
Su L, Turner JR. Su L, et al. Gastroenterology. 2007 Apr;132(4):1615-8. doi: 10.1053/j.gastro.2007.03.015. Gastroenterology. 2007. PMID: 17418164 No abstract available.
Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women.
Wiseman LR, McTavish D. Wiseman LR, et al. Drugs Aging. 1994 Mar;4(3):238-56. doi: 10.2165/00002512-199404030-00006. Drugs Aging. 1994. PMID: 8199397 Review.
The combined transdermal estradiol/norethisterone therapeutic system is designed to deliver both estradiol and norethisterone into the systemic circulation at a constant rate for up to 4 days when affixed to the skin. ...Menopausal symptoms are improve …
The combined transdermal estradiol/norethisterone therapeutic system is designed to deliver both estradiol and noret …
Effects of estradiol, progestogens, and of tibolone on breast proliferation and apoptosis.
Pompei LM, Cunha EP, Steiner ML, Theodoro TR, Mader AM, Petri G, Pinhal MA, Fernandes CE. Pompei LM, et al. Climacteric. 2015;18(4):518-22. doi: 10.3109/13697137.2015.1020482. Epub 2015 Apr 1. Climacteric. 2015. PMID: 25830529
METHODS: Thirty 250-day-old Wistar rats were castrated and 3 weeks later received one of the following treatments by gavage for 5 weeks: (1) estradiol benzoate; (2) estradiol benzoate + medroxyprogesterone acetate; (3) estradiol benzoate + norethisterone …
METHODS: Thirty 250-day-old Wistar rats were castrated and 3 weeks later received one of the following treatments by gavage for 5 weeks: (1) …
Existing once-a-month combined injectable contraceptives.
Toppozada MK. Toppozada MK. Contraception. 1994 Apr;49(4):293-301. doi: 10.1016/0010-7824(94)90029-9. Contraception. 1994. PMID: 8013216 Review.
It took over 15 years to resolve many of these problems and add a new product (Mesigyna = 50 mg norethisterone enantate plus 5 mg estradiol valerate in an oily solution). Cycloprovera, at a lower dose, received the new name of Cyclofem and Deladroxate was manufactur …
It took over 15 years to resolve many of these problems and add a new product (Mesigyna = 50 mg norethisterone enantate plus 5 mg …
3,112 results